April W Armstrong1, Michael P Siegel2, Jerry Bagel3, Erin E Boh4, Megan Buell2, Kevin D Cooper5, Kristina Callis Duffin6, Lawrence F Eichenfield7, Amit Garg8, Joel M Gelfand9, Alice B Gottlieb10, John Y M Koo11, Neil J Korman5, Gerald G Krueger6, Mark G Lebwohl12, Craig L Leonardi13, Arthur M Mandelin14, M Alan Menter15, Joseph F Merola16, David M Pariser17, Ronald B Prussick18, Caitriona Ryan15, Kara N Shah19, Jeffrey M Weinberg12, MaryJane O U Williams20, Jashin J Wu21, Paul S Yamauchi22, Abby S Van Voorhees23. 1. Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: aprilarmstrong@post.harvard.edu. 2. National Psoriasis Foundation, Portland, Oregon. 3. Windsor Dermatology, East Windsor, New Jersey; University Medical Center of Princeton at Plainsboro, Plainsboro, New Jersey. 4. Tulane University School of Medicine, New Orleans, Louisiana. 5. University Hospitals Case Medical Center, Cleveland, Ohio. 6. University of Utah School of Medicine, Salt Lake City, Utah. 7. University of California, San Diego School of Medicine, La Jolla, California. 8. Northwell Health and Hofstra North Shore University Hospital, Long Island Jewish Medical Center School of Medicine, Manhasset, New York. 9. University of Pennsylvania, Philadelphia, Pennsylvania. 10. Tufts University School of Medicine, Boston, Massachusetts. 11. University of California San Francisco Medical Center, San Francisco, California. 12. Icahn School of Medicine at Mount Sinai, New York, New York. 13. St Louis University Medical School, St Louis, Missouri. 14. Northwestern University Feinberg School of Medicine, Chicago, Illinois. 15. Baylor University Medical Center and Texas A&M Health Science Center, Dallas, Texas. 16. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 17. Eastern Virginia Medical School, Norfolk, Virginia; Virginia Clinical Research Inc, Norfolk, Virginia. 18. George Washington University, Washington, District of Columbia. 19. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 20. Keck School of Medicine, University of Southern California, Los Angeles, California. 21. Kaiser Permanente Los Angeles Medical Center, Los Angeles, California. 22. Division of Dermatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California. 23. Eastern Virginia Medical School, Norfolk, Virginia.
Abstract
BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds. RESULTS: A total of 25 psoriasis experts participated in the Delphi process. The most preferred instrument was body surface area (BSA). The most preferred time for evaluating patient response after starting new therapies was at 3 months. The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline. The target response at 3 months postinitiation was BSA 1% or less. During the maintenance period, evaluation every 6 months was most preferred. The target response at every 6 months maintenance evaluation is BSA 1% or less. LIMITATIONS: Although BSA is feasible in practice, it does not encompass health-related quality of life, costs, and risks of side effects. CONCLUSION: With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.
BACKGROUND: An urgent need exists in the United States to establish treatment goals in psoriasis. OBJECTIVE: We aim to establish defined treatment targets toward which clinicians and patients with psoriasis can strive to inform treatment decisions, reduce disease burden, and improve outcomes in practice. METHODS: The National Psoriasis Foundation conducted a consensus-building study among psoriasis experts using the Delphi method. The process consisted of: (1) literature review, (2) pre-Delphi question selection and input from general dermatologists and patients, and (3) 4 Delphi rounds. RESULTS: A total of 25 psoriasis experts participated in the Delphi process. The most preferred instrument was body surface area (BSA). The most preferred time for evaluating patient response after starting new therapies was at 3 months. The acceptable response at 3 months postinitiation was either BSA 3% or less or BSA improvement 75% or more from baseline. The target response at 3 months postinitiation was BSA 1% or less. During the maintenance period, evaluation every 6 months was most preferred. The target response at every 6 months maintenance evaluation is BSA 1% or less. LIMITATIONS: Although BSA is feasible in practice, it does not encompass health-related quality of life, costs, and risks of side effects. CONCLUSION: With defined treatment targets, clinicians and patients can regularly evaluate treatment responses and perform benefit-risk assessments of therapeutic options individualized to the patient.
Authors: Ladan Afifi; Lindsey Shankle; April W Armstrong; Marc Boas; Alisha Bridges; Vivian Chiguil; Frank Doris; Kristina Callis Duffin; Eric Fielding; Roy Fleischmann; Joel M Gelfand; Matthew Kiselica; Catherine Kiselica; Brian LaFoy; John J Latella; Junko Takeshita; Sarah Truman; Marilyn T Wan; Vickie Wilkerson; Jashin J Wu; Michael P Siegel; Wilson Liao Journal: J Psoriasis Psoriatic Arthritis Date: 2017
Authors: Rebecca Haberman; Lourdes M Perez-Chada; Joseph F Merola; Jose Scher; Alexis Ogdie; Soumya M Reddy Journal: Curr Rheumatol Rep Date: 2018-10-26 Impact factor: 4.592
Authors: Marloes E van Muijen; S Atalay; L J van Vugt; L M D Vandermaesen; J M P A van den Reek; E M G J de Jong Journal: Drugs Real World Outcomes Date: 2021-03-28
Authors: Selma Atalay; Lara S van der Schoot; Laura Vandermaesen; Lieke J van Vugt; Mascha Eilander; Juul M P A van den Reek; Elke M G J de Jong Journal: Acta Derm Venereol Date: 2021-05-25 Impact factor: 3.875
Authors: Marjolein De Bruin-Weller; Tilo Biedermann; Robert Bissonnette; Mette Deleuran; Peter Foley; Giampiero Girolomoni; Jana Hercogová; Chih-Ho Hong; Norito Katoh; Andrew E Pink; Marie-Aleth Richard; Stephen Shumack; Juan F Silvestre; Stephan Weidinger Journal: Acta Derm Venereol Date: 2021-02-17 Impact factor: 3.875
Authors: Nikolai Loft; Alexander Egeberg; Mads Kirchheiner Rasmussen; Lars Erik Bryld; Christoffer V Nissen; Tomas Norman Dam; Kawa Khaled Ajgeiy; Lars Iversen; Lone Skov Journal: Acta Derm Venereol Date: 2021-01-04 Impact factor: 3.875
Authors: Josef S Smolen; Monika Schöls; Jürgen Braun; Maxime Dougados; Oliver FitzGerald; Dafna D Gladman; Arthur Kavanaugh; Robert Landewé; Philip Mease; Joachim Sieper; Tanja Stamm; Maarten de Wit; Daniel Aletaha; Xenofon Baraliakos; Neil Betteridge; Filip van den Bosch; Laura C Coates; Paul Emery; Lianne S Gensler; Laure Gossec; Philip Helliwell; Merryn Jongkees; Tore K Kvien; Robert D Inman; Iain B McInnes; Mara Maccarone; Pedro M Machado; Anna Molto; Alexis Ogdie; Denis Poddubnyy; Christopher Ritchlin; Martin Rudwaleit; Adrian Tanew; Bing Thio; Douglas Veale; Kurt de Vlam; Désirée van der Heijde Journal: Ann Rheum Dis Date: 2017-07-06 Impact factor: 19.103